Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Review Article

Glaucoma Drug Therapy in Pregnancy: Literature Review and Teratology Information Service (TIS) Case Series

Author(s): Marcella Pellegrino*, Luisa D`Oria, Carmen De Luca, Giacomina Chiaradia, Angelo Licameli, Caterina Neri, Marta Nucci, Daniela Visconti, Alessandro Caruso and Marco De Santis

Volume 13, Issue 1, 2018

Page: [3 - 11] Pages: 9

DOI: 10.2174/1574886312666171030125804

Price: $65

Abstract

Background: There are many contradictions about pregnancy and fetal/neonatal outcomes after topical use of timolol alone or timolol in combination with other antiglaucoma medications.

Methods: Seventy-five pregnant women exposed to antiglaucoma medications were followed prospectively by phone interviews. 27 women used timolol as monotherapy, 48 women used timolol as a part of multidrug therapy. We selected a control group of 187 healthy pregnant women.

Results: Topical use of timolol alone or timolol in combination with other antiglaucoma medications does not influence pregnancy or fetal/neonatal outcomes.

Conclusion: Beta-blocker is the first choice treatment for glaucoma in pregnancy but, when necessary, multidrug therapy should not to be excluded.

Keywords: Congenital anomalies, drugs, glaucoma, pregnancy, prenatal diagnosis, Teratology Information Service (TIS).

Graphical Abstract

Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy